According to yesterday’s press release, the trial notes “MAKOplasty resulted in significantly lower post-operative pain from day one to eight weeks post-op and it took eight weeks for Oxford patients to reach the lower pain levels that MAKOplasty patients were already reporting after six days.” What’s more, MAKOplasty also proved more accurate “in all dimensions measured, with statistically significant differences in four of the six dimensions.”
Of course, Biomet is a privately held company, but it’s safe to say that trials like this should have other publicly traded companies like Stryker Corporation (NYSE:SYK), Zimmer Holdings, Inc. (NYSE:ZMH), and Johnson & Johnson (NYSE:JNJ) sweating bullets given their competing manually placed implants. It also doesn’t help their case that Johnson & Johnson in March lost its first of 10,750 lawsuits over defective metal-on-metal hip implants, but you can bet MAKO Surgical Corp. (NASDAQ:MAKO) can’t wait to capitalize on the fallout with its own innovative offerings.
Foolish final thoughts
In the end, MAKO shareholders are breathing a long-awaited sigh of relief after the company performed exactly as it said it would. Even so, with the stock trading more than 60% below its 52-week-high, you can bet we’ll be watching closely to see whether MAKO can keep up the good work. If it can, the stock could very easily prove to be the multibagger that investors have been waiting for.
The article MAKO Surgical Posts a Solid Quarter: Here’s What Investors Need to Know originally appeared on Fool.com and is written by Steve Symington.
Fool contributor Steve Symington owns shares of MAKO Surgical . The Motley Fool recommends Johnson & Johnson and MAKO Surgical . The Motley Fool owns shares of Johnson & Johnson (NYSE:JNJ) and Zimmer Holdings, Inc. (NYSE:ZMH).
Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.